- Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus (AAV) engineering platform
NORTH CHICAGO, Ill., Feb. 16, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share.
NORTH CHICAGO, Ill., Feb. 9, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2022.
IRVINE, Calif., Jan. 25, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.
IRVINE, Calif., Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM® VOLUX™ XC. The long-lasting hyaluronic acid (HA) filler is now available at aesthetic practices for consumers over the age of 21 with moderate to severe loss of jawline definition.1
IRVINE, Calif., Jan. 17, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica® Even & Correct Collection. Clinically proven and formulated to deliver targeted results, these three products work separately and together to even skin tone and reduce the appearance of hyperpigmentation and dark spots on the face: Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads.
- Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology
- Anima will receive an upfront payment of $42 million with potential for further milestones and royalties
- Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine
- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties
NORTH CHICAGO, Ill., Jan. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.
Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.
Stay up to date on recent news, articles, and more by subscribing to email alerts for one or more of our news topics.
Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds.
You must be logged in to view this item.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?